Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2007

New $114M Center for Regenerative Medicine to be Established in Scotland

  • A $114-million Scottish Center for Regenerative Medicine (SCRM) will be developed by the University of Edinburgh in collaboration with Scottish Enterprise. The SCRM will provide research facilities, manufacturing capacity, and commercialization facilities.

    The Scottish Executive will provide support for the SCRM with more than $46M in funding. “This backing will allow Scotland to build on its international lead,” says University of Edinburgh principal, Timothy O'Shea.

    The SCRM, which will be part of the new Center for Biomedical Research at Edinburgh’s Little France, will be unique in Europe and is thought to be equaled only by Kobe in Japan. It will have three main elements: high-quality accommodation to support 220 academic researchers, a center for scale-up development and manufacturing of cells, and multi-occupancy space to house commercial regenerative medicine research organizations and spin-outs.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »